Skip to main content
. Author manuscript; available in PMC: 2014 Aug 14.
Published in final edited form as: Periodontol 2000. 2013 Jun;62(1):163–202. doi: 10.1111/prd.12005

Fig. 4.

Fig. 4

Model of the RANK/RANKL/osteoprotegerin pathway for osteoclastic alveolar bone loss in periodontal disease. Also shown are potential sites for blocking these deleterious reactions with various ‘biologicals’ based upon receptor–ligand engagement and intracellular signaling pathways. OPG, osteoprotegerin.